LTS Expands CDMO Capabilities Through Renaissance Lakewood Acquisition

LTS Expands Its CDMO Capabilities with Renaissance Lakewood Acquisition

LTS LOHMANN Therapie-Systeme AG, a prominent player in the pharmaceutical technology sector, has officially announced its acquisition of Renaissance Lakewood, LLC, a contract development and manufacturing organization (CDMO) based in the United States. This strategic move is set to bolster LTS's capabilities in the field of drug delivery solutions, particularly in nasal sprays and sterile dosage forms.

Founded in 1979 and currently under the ownership of RoundTable Healthcare Partners, Renaissance has established itself as a leader in the CDMO space. The company operates from its base in Lakewood, New Jersey, and boasts cutting-edge manufacturing infrastructure alongside a talented workforce of approximately 500 employees. The acquisition will integrate Renaissance into LTS’s global operational network, which includes facilities located in Andernach, Germany, West Caldwell, NJ, St. Paul, MN, and Netanya, Israel.

LTS's acquisition of Renaissance is not just significant for its operational reach but also for its innovation potential. With Renaissance's expertise, LTS can now offer an expanded range of drug delivery systems that cater to diverse therapeutic areas. Bas van Buijtenen, CEO of LTS, expressed enthusiasm about the integration, highlighting Renaissance’s commitment to quality and innovation in drug delivery. He emphasized that this acquisition will allow LTS to provide enhanced value to both partners and patients around the globe.

The facilities of Renaissance specialize in manufacturing multiple formats for nasal sprays, including unit-dose, bi-dose, and multi-dose systems, as well as small-volume parenteral fill-finish vials. Its laboratories focus on research and development tailored to formulation and spray characterization, assisting clients from development through to commercial launch. This positions Renaissance as a holistic partner for pharmaceutical developers, further enriching LTS's offerings.

Serge Maltais, President and CEO of Renaissance, expressed confidence that joining forces with LTS will position Renaissance even more advantageously to meet client needs. He acknowledged the hard work and dedication of Renaissance’s staff and conveyed excitement about the future prospects of the partnership.

Moreover, LTS's strategy aims to pave the way for a seamless integration of Renaissance's capabilities, enhancing its ability to serve partners in the pharmaceutical and biotech sectors effectively. As LTS continues to uphold its philosophy of care, creation, and delivery, this acquisition reinforces its commitment to innovation in drug delivery solutions. It also emphasizes the importance of expanding manufacturing competencies to adapt to the evolving market landscape.

The transaction is projected to finalize before the end of November 2025, pending regulatory approvals. This acquisition underscores LTS's ambition to solidify its leadership position within the CDMO community and its ongoing commitment to advancing drug delivery technologies that meet the complexity of modern therapeutic needs.

In conclusion, the strategic acquisition of Renaissance Lakewood marks a pivotal moment for LTS, improving their operational capacity and positioning them for future growth in a competitive industry. As pharmaceutical needs evolve, LTS is intent on staying ahead by integrating advanced capabilities and continuing to innovate in drug delivery systems that can address a broader range of health challenges.

To learn more about LTS and their innovative solutions, visit LTS Lohmann or Renaissance.